There was an error in the original publication [1]. The reference Sørbye et al. [21] was incorrectly described in the manuscript as using the APTIMA mRNA assay.
A correction has been made to Paragraph 7 of Section 1. Introduction:
Previous studies, including a screen-and-treat trial by Sørbye et al. [21], have demonstrated the utility of genotype-specific HPV E6/E7 mRNA testing in improving screening specificity and reducing overtreatment in South African women.
A correction has been made to Paragraph 10 of Section 3. Discussion:
This observation could obscure age-specific patterns typically observed in general populations [32,33], thus emphasizing the importance of adapting cervical cancer screening strategies, including the selection of appropriate HPV test types and screening thresholds, to local epidemiological data [21].
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Reference
- Nkwinika, V.V.; Amissah, K.A.; Rakgole, J.N.; Khaba, M.C.; Magwira, C.A.; Lebelo, R.L. APTIMA mRNA vs. DNA-Based HPV Assays: Analytical Performance Insights from a Resource-Limited South African Setting. Int. J. Mol. Sci. 2025, 26, 7450. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.